Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.
Tsushima N et al.
Auris, Nasus, Larynx, 2024
Unbiased interrogation of functional lysine residues in human proteome.
Bao Y et al.
Molecular Cell, 2023
Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis.
Gutierrez-Rodrigues F et al.
Haematologica, 2022
Acetylation-dependent regulation of BRAF oncogenic function.
Dai X et al.
Cell Reports, 2022
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A et al.
Plos Medicine, 2020
Molecular and immunohistochemical analysis of BRAF gene in primary cutaneous melanoma: Discovery of novel mutations.
Fatnassi-Mersni G et al.
Journal of Cutaneous Pathology, 2020
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J et al.
Genome Medicine, 2018
Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
Ma W et al.
Molecular Diagnosis & Therapy, 2017
Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.
Gaiser MR et al.
Plos One, 2017
Mutational patterns in oncogenes and tumour suppressors.
Baeissa HM et al.
Biochemical Society Transactions, 2016
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
Han PA et al.
Thyroid : Official Journal of the American Thyroid Association, 2016
The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.
Kiel C et al.
Elife, 2016
Kinome-wide decoding of network-attacking mutations rewiring cancer signaling.
Creixell P et al.
Cell, 2015
Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.
Li C et al.
The Journal of Clinical Endocrinology and Metabolism, 2013
Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600).
Skorokhod A et al.
Plos One, 2013
Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation.
Ko YS et al.
Pathology International, 2012
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression.
Lin J et al.
British Journal of Cancer, 2011
A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
Brzezianska E et al.
Frontiers in Bioscience (landmark Edition), 2011
Polyclonality of BRAF mutations in acquired melanocytic nevi.
Lin J et al.
Journal of the National Cancer Institute, 2009
Somatic mutations to CSMD1 in colorectal adenocarcinomas.
Farrell C et al.
Cancer Biology & Therapy, 2008